Drug-Related Side Effects and Adverse Reactions, Epidermal Growth Factor
Conditions
Keywords
Epidermal Growth Factor
Brief summary
The purpose of this study is to evaluate the preventive efficacy of topical EGF cream for dermatologic adverse events related to EGFR inhibitors.
Detailed description
Epidermal growth factor receptor(EGFR) is involved in cell proliferation and is overexpressed or abnormally activated in malignant tumors originating from the colon, breast, ovary, pancreas, and lung. EGFR tyrosine kinase inhibitor(TKI), gefitinib, erlotinib, and afatinib have been for the treatment of cancer associated with EGFR gene mutation. In addition, monoclonal antibodies to EGFR, such as cetuximab and panitumumab, have been used as a chemotherapy for rectal cancer without ras gene mutation and advanced head and neck cancer. The incidence of cutaneous toxicity of EGFR inhibitors is reported to be 75-80%. Clinical features include acneform folliculitis, xerosis, paronychia, and itching. Of these, about 10% of patients with Grade 3 or greater have a detrimental effect on quality of life and adherence to treatment, resulting in impaired therapeutic results. There have been many attempts to prevent or treat such skin toxicity. However, there has been no scientifically proven treatment until now. There is a growing interest in the role of EGF emulsifiers in the treatment of skin adverse effects of EGFR inhibitors, as a result of studies that improve acne significantly compared to placebo. The purpose of this study is to evaluate the preventive efficacy of EGF cream in the treatment of skin adverse effects in patients with malignant tumors treated with EGFR inhibitor (TKI or monoclonal antibody).
Interventions
A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks. EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)
A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks. Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF
Sponsors
The Catholic University of Korea
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Over 20 years old * Patients scheduled to receive EGFR inhibitors (gefitinib, erlotinib, afatinib, cetuximab, etc.) as malignant tumors * Patients who can understand and follow the protocol * Patients who spontaneously agreed to the study
Exclusion criteria
* Patients with a history of antibiotic treatment, local and systemic steroid therapy within 4 weeks of other skin disorders * Patients with existing acne history * Breastfeeding or pregnant women * Patients who are deemed unsuitable for the examination by the researcher's judgment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change of acneiform eruption caused by use of EGFR inhibitor | Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks | To evaluate the development and severity of acneiform eruption, the investigators take a photograph of full face and hands on every visit. If the acneiform eruption develop, the severity will be assessed based on the Korean Acne Grading System(KAGS). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the change of skin hydration | Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks | It measured with Corneometer® (CM820/825, C-K Electronics, Cologne, Germany). It shows in arbitrary units(AU) and the unit is from 0 to 220. |
| the change of sebum production | Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks | It measured with Sebumeter® (SM815; C-K Electronics, Cologne, Germany). It is measured at forehead, cheek and chin, presented as /㎍ ㎠. It shows in arbitrary units(AU) and the unit is from 0 to 220. |
| the change paronychia caused by use of EGFR inhibitor | Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks | The paronychia lesion will be assessed by CTCAE. |
| Patient's global assessment score | Baseline, 8 weeks | Patient's global assessment (PGA) score will be assessed with a 5-point scale (-1 = worsen, to 3 = marked improvement). |
| The side effects of product | Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks | It will be assessed by patient-report. \- Any event developed during the trials can be reported. |
| Investigator's global assessment score | Baseline, 8 weeks | Investigator's global assessment (IGA) Score will be assessed with 5-point scale (-1 = worsen to 3 =marked improvement). |
Countries
South Korea
Contacts
Primary ContactJung Min Bae, MD, PhD
Backup ContactHo jung An, MD, PhD
Outcome results
None listed